Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
14 Agosto 2023 - 7:00AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that
Laurent Fischer, M.D., president and chief executive officer of
Adverum Biotechnologies, will present at the H.C. Wainwright 3rd
Annual Ophthalmology Virtual Conference on Wednesday, August 16,
2023.
The on-demand webcast of the presentation may be accessed under
Events and Presentations in the Investors section of Adverum’s
website. A replay of the webcast will be available on the website
for 90 days following the presentation.
About Adverum BiotechnologiesAdverum
Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that
aims to establish gene therapy as a new standard of care for highly
prevalent ocular diseases with the aspiration of developing
functional cures to restore vision and prevent blindness.
Leveraging the capabilities of its proprietary intravitreal (IVT)
platform, Adverum is developing durable, single-administration
therapies, designed to be delivered in physicians’ offices, to
eliminate the need for frequent ocular injections to treat these
diseases. Adverum is evaluating its novel gene therapy candidate,
ixoberogene soroparvovec (Ixo-vec, formerly referred to as
ADVM-022), as a one-time, IVT injection for patients with
neovascular or wet age-related macular degeneration. By overcoming
the challenges associated with current treatment paradigms for
debilitating ocular diseases, Adverum aspires to transform the
standard of care, preserve vision, and create a profound societal
impact around the globe. For more information, please visit
www.adverum.com.
Corporate, Investor and Media Inquiries Anand
ReddiVice President, Head of Corporate Strategy, External Affairs
and EngagementAdverum Biotechnologies, Inc.T:
650-649-1358E: areddi@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De May 2023 a May 2024